-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
89bio, Inc. (NASDAQ:ETNB) Short Interest Update
89bio, Inc. (NASDAQ:ETNB) Short Interest Update
89bio, Inc. (NASDAQ:ETNB – Get Rating) was the recipient of a significant decrease in short interest during the month of December. As of December 30th, there was short interest totalling 4,430,000 shares, a decrease of 7.1% from the December 15th total of 4,770,000 shares. Based on an average trading volume of 911,000 shares, the days-to-cover ratio is presently 4.9 days.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $34.00 price objective (up previously from $27.00) on shares of 89bio in a report on Monday, November 14th. Royal Bank of Canada dropped their price objective on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating for the company in a report on Friday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.25.
Get 89bio alerts:89bio Trading Down 1.1 %
NASDAQ:ETNB traded down $0.14 on Tuesday, reaching $12.15. 808,300 shares of the stock traded hands, compared to its average volume of 859,320. 89bio has a 1-year low of $2.00 and a 1-year high of $12.95. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.81 and a current ratio of 5.81. The company's 50 day moving average is $10.12 and its 200-day moving average is $7.34.
89bio (NASDAQ:ETNB – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.32. Research analysts expect that 89bio will post -2.65 earnings per share for the current fiscal year.Insider Transactions at 89bio
In other news, CFO Ryan Martins sold 5,947 shares of the stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $12.51, for a total value of $74,396.97. Following the completion of the transaction, the chief financial officer now owns 36,368 shares of the company's stock, valued at $454,963.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.80% of the company's stock.
Institutional Trading of 89bio
Several large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in shares of 89bio during the 3rd quarter worth approximately $96,000. Captrust Financial Advisors acquired a new stake in 89bio in the 3rd quarter valued at $60,000. Jane Street Group LLC acquired a new stake in 89bio in the 3rd quarter valued at $115,000. State Street Corp grew its position in 89bio by 104.2% in the 3rd quarter. State Street Corp now owns 62,910 shares of the company's stock valued at $364,000 after purchasing an additional 32,100 shares during the period. Finally, Orchard Capital Management LLC grew its position in 89bio by 227.5% in the 3rd quarter. Orchard Capital Management LLC now owns 551,879 shares of the company's stock valued at $3,195,000 after purchasing an additional 383,386 shares during the period. Institutional investors and hedge funds own 87.78% of the company's stock.
About 89bio
(Get Rating)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
Recommended Stories
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
89BioInc.(纳斯达克代码:ETNB-GET Rating)是12月份空头股数销量大幅下降的接收方。截至12月30日,空头股数共有443万股,比12月15日的477万股减少了7.1%。以911,000股的平均成交量计算,目前的天数与回补比率为4.9天。
华尔街分析师预测经济增长
一些研究分析师最近发布了关于该股的报告。康托·菲茨杰拉德在11月14日周一的一份报告中重申了对89Bio的增持评级,并发布了每股34.00美元的目标价(此前为27.00美元)。在11月11日星期五的一份报告中,加拿大皇家银行将89Bio的股票目标价从35.00美元下调至29.00美元,并为该公司设定了“跑赢大盘”的评级。七位投资分析师对该股的评级为买入,一位分析师对该股的评级为买入。根据MarketBeat的数据,该股目前的共识评级为买入,共识目标价为25.25美元。
到达89Bio警报:89Bio股价下跌1.1%
纳斯达克:etnb周二下跌0.14美元,至12.15美元。该股共有808,300股易手,而其平均成交量为859,320股。89Bio的一年低点为2.00美元,一年高位为12.95美元。该公司的负债权益比率为0.08,速动比率为5.81,流动比率为5.81。该公司的50日移动均线切入位在10.12美元,200日移动均线切入位在7.34美元。
89Bio(纳斯达克代码:ETNB-GET Rating)上一次公布季度收益数据是在11月10日星期四。该公司公布本季度每股收益(0.57美元),比普遍预期的(0.89美元)高出0.32美元。研究分析师预计,89Bio本财年的每股收益将达到2.65美元。89Bio的内幕交易
在其他新闻方面,首席财务官瑞安·马丁斯在1月3日星期二的交易中出售了5947股该公司股票。这些股票的平均价格为12.51美元,总价值为74,396.97美元。交易完成后,首席财务官现在拥有该公司36,368股股票,价值454,963.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过以下方式获取此超链接。公司内部人士持有该公司11.80%的股份。
89Bio的机构交易
几家大型投资者最近调整了对该股的持股比例。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度收购了89Bio股权,价值约9.6万美元。CapTrust Financial Advisors在第三季度收购了89Bio的新股份,价值6万美元。简街集团(Jane Street Group LLC)在第三季度以11.5万美元的价格收购了89io的新股份。道富银行在第三季度的持仓增加了104.2%。道富银行目前持有62,910股该公司股票,价值364,000美元,在此期间又购买了32,100股。最后,Orchard Capital Management LLC在第三季度将其在89Bio的头寸增加了227.5%。Orchard Capital Management LLC现在拥有该公司551,879股股票,价值3,195,000美元,在此期间又购买了383,386股。机构投资者和对冲基金持有该公司87.78%的股票。
约89Bio
(获取评级)
89BioInc.是一家临床阶段的生物制药公司,专注于治疗肝脏和心脏代谢性疾病的疗法的开发和商业化。它的主要候选产品是pegozafermin,一种用于治疗非酒精性脂肪性肝炎的成纤维细胞生长因子21的糖基化类似物。
推荐故事
- 免费获取股票新闻网站89Bio(ETNB)上的研究报告
- Intuit即将采取行动,但走哪条路呢?
- 1月下旬收益表现出流行音乐的潜力
- 低价股仍在派发股息
- 为什么Chipotle的股价本周飙升?
- 诺斯罗普·格鲁曼公司的抛售是一个机会吗?
接受89Bio日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对89Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧